As the COVID-19 cases continue to rise globally, the National Medical Products Administration of China has approved the first-ever antiviral medicine called Favilavir. This medicine is said to possibly treat the now-declared pandemic illness, The Science Times report.
Over the weekend, Taizhou's city government announced that Favilavir, which was initially formulated by a Chinese-owned pharmaceutical firm, is the first medicine authorized to stop the widespread of this fatal illness. At present, this drug is being promoted with the label, Avigan.
According to the Science Times, Favilavir functions as an effective antiviral drug to fight RNA infections by inhibiting the RNA-dependent RNA polymerase or the RdRp. Besides, this drug is mainly taken as an effective treatment for influenza in Japan and China. The trials are being conducted to identify how effective Favilavir is against COVID-19.
According to the Ministry of Science and Technology of China, the Favilavir of Hisun Pharmaceutical is among the three drugs that have presented results for hindering COVID-19 (in initial trials) from spreading and further damaging the health of the people worldwide.
Relatively, this drug was tested in a then, the ongoing clinical test being held in Shenzhen, Guangdong Province which engaged around 70 patients, after which it was discovered to be possibly effective in COVID-19 treatments, though some minor effects had also been recorded. At present, the generic version of Faviliavir is being mass-produced in China.
Chinese regulatory officials first announced their approval of the antiviral Favilavir to be used as a treatment for the COVID-19 back in February.